The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Researchers at the University of Toronto's Institute of Biomedical Engineering have found that studying blood flow in leg ...

Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardia ...